Clinical trial

CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)

NCT05704192

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

PROCEDURE · Unmapped registry intervention TACE ± Systemic therapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)

Design: OBSERVATIONAL · Status: UNKNOWN · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2023-05-04

PhaseN/A

Conditions

Hepatocellular Carcinomaverified · MONDO: hepatocellular carcinoma

Portal Hypertensionverified · MONDO: portal hypertension

Interventions

TACE ± Systemic therapyPROCEDURE

Sponsors & collaborators

Zhongda Hospitallead sponsor

Mapped research locations

NanjingChina2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05704192 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.